Skip to main content
. 2015 Mar 26;6(12):9970–9984. doi: 10.18632/oncotarget.3667

Figure 4. TRAIL and delphinidin activate DR5 expression and intrinsic apoptotic pathway.

Figure 4

(A) Delphinidin induces DR5 in LNCaP and Du145 cells. LNCaP and Du145 cells were treated for 12 h with different concentration of delphinidin (0, 10, 30, 50 μM), and western blot analysis was performed using antibodies against DR5. (B and C) DR5 and BAX expression is critical for the sensitization of TRAIL-mediated apoptosis. LNCaP cells transfected with the scrambled siRNA, DR5 siRNA, or BAX siRNA were further treated with 30 μM delphinidin and 50 ng/ml TRAIL for 12 h. (B) Western blot analysis demonstrated inhibition of caspase-3 cleavage by knockdown of DR5 or BAX and (C) their corresponding antiapoptotic effects. The apoptotic cell death was determined by MTT assay (left) and TUNEL assay (right) kit as described in Materials and Methods. (D) Co-treatment of delphinidin and TRAIL regulates the expression of various apoptosis-related genes at transcriptional level. LNCaP cells were treated with TRAIL (T, 50 ng/ml) and/or delphinidin (D, 30 μM) for 12 h. The expression level of each gene was analyzed by qRT-PCR using total mRNA from LNCaP cells, treated with delphinidin and/or TRAIL, and compared with control LNCaP cells. Fold-change was calculated by 2−ΔΔCt relative quantitative analysis. The data are expressed as the mean ± SD for triplicates (*P<0.05 vs. −TRAIL/−DEL).